Prednisone in Duchenne dystrophy (Q43876778)

27 November 2017

0 references

1 reference

title

Prednisone in Duchenne dystrophy (English)

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

2 December 2022

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

2 December 2022

author name string

V. Dubowitz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1822789

2 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1822789

2 December 2022

publication date

1 January 1991

1 reference

full work available at URL

27 November 2017

https://api.elsevier.com/content/article/PII:096089669190019O?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

https://api.elsevier.com/content/article/PII:096089669190019O?httpAccept=text/plain

2 December 2022

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

2 December 2022

published in

Neuromuscular Disorders

1 reference

27 November 2017

1

1 reference

27 November 2017

3

1 reference

27 November 2017

161-163

1 reference

Management of muscular dystrophy. Pharmacological and physical aspects

27 November 2017

1

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Management of children: pharmacological and physical

2 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Prednisone in Duchenne muscular dystrophy

2 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone

2 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit

2 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

2 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

2 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group

2 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group

2 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro

2 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

Glucocorticoids increase myoblast proliferation rates by inhibiting death of cycling cells

2 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0960-8966(91)90019-O

2 December 2022

Identifiers

1 reference

27 November 2017

1 reference